| Identification | Back Directory | [Name]
AAPK-25 | [CAS]
2247919-28-2 | [Synonyms]
AAPK-25
2-Naphthalenecarboxamide, 6-[(3,4-dichlorobenzoyl)amino]-N-2-thiazolyl-
Aurora Kinase,inhibit,Polo-like Kinase (PLK),AAPK 25,Apoptosis,Inhibitor,AAPK25,AAPK-25 | [Molecular Formula]
C21H13Cl2N3O2S | [MDL Number]
MFCD32197231 | [MOL File]
2247919-28-2.mol | [Molecular Weight]
442.32 |
| Chemical Properties | Back Directory | [density ]
1.536±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
6.98±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM[1]. | [in vivo]
AAPK-25 enhances survival rate in the BALB/c nude mice tumor xenograft model[1]. | [storage]
Store at -20°C | [References]
[1] Qi B, et al. Discovery of inhibitors of Aurora/PLK targets as anti-cancer agents. J Med Chem. 2019 Aug 5. DOI:10.1021/acs.jmedchem.9b00353 |
|
|